Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study

Abstract Background Severe asthma (SA) is a heterogeneous disease composed of various clinical phenotypes, and criteria for selecting the most appropriate biological agent remain unclear. Therefore, when optimal control cannot be achieved with the initial biological therapy, switching between biolog...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Fatma Arzu Akkuş, Fatih Çölkesen, Tuğba Önalan, Mehmet Emin Gerek, Mehmet Kılınç, Şevket Arslan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-11-01
coleção:	BMC Pulmonary Medicine
Assuntos:	Benralizumab Biologic therapy Eosinophils Mepolizumab Omalizumab Severe asthma
Acesso em linha:	https://doi.org/10.1186/s12890-025-04044-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!